| S9779 |
Emavusertib (CA-4948) |
Emavusertib (CA-4948) is a potent and orally bioavailable inhibitor of interleukin-1 receptor-associated kinase 4/FMS-like Tyrosine Kinase 3 (IRAK4/FLT3) with anti-tumor activity. |
Selective |
|
| S8562 |
IRAK4-IN-2 |
IRAK4-IN-2 is a reversible kinase inhibitor that modulates IRAK4 function in both the toll-like receptor (TLR) and interleukin 1 receptor (IL-1R) signaling cascades. |
Selective |
|
| S8531 |
Zimlovisertib (PF-06650833) |
Zimlovisertib (PF-06650833) is a potent, selective inhibitor of IRAK4 with an IC50 of 0.2 nM. |
Selective |
IRAK4, IC50: 0.2 nM |
| S0775 |
IRAK4-IN-4 |
IRAK4-IN-4 (compound 15) is an inhibitor of interleukin-1 receptor–associated kinase 4 (IRAK4) and cyclic GMP-AMP synthase (cGAS) with IC50 of 2.8 nM and 2.1 nM, respectively. |
Selective |
IRAK4, IC50: 2.8 nM |
| S0008 |
IRAK4-IN-1 |
IRAK4-IN-1 is an interleukin-1 receptor associated kinase 4 (IRAK4) inhibitor with IC50 of 7 nM. |
Selective |
IRAK4, IC50: 7 nM |
| S2039 |
IRAK inhibitor 6 |
IRAK inhibitor 6 is a selective Interleukin-1 receptor-associated kinase 4(IRAK4) inhibitor with IC50 of 0.16 μM. |
Selective |
IRAK4, IC50: 0.16 μM |
| S9701 |
HS-243 |
HS-243 is a highly potent interleukin-1 receptor-associated kinase (IRAK) inhibitor with IC50 of 24 nM, 20 nM and 0.5 μM for IRAK-1, IRAK-4 and TAK1, respectively. |
Pan |
IRAK-4, IC50: 20 nM |
| S8663 |
Takinib |
Takinib is a potent and selective TAK1 inhibitor with an IC50 of 9.5 nM, more than 1.5 log more potent than the second and third ranked targets, IRAK4 (120 nM) and IRAK1 (390 nM), respectively. Takinib induces apoptosis. |
Pan |
IRAK4, IC50: 120 nM |
| S6598 |
IRAK-1-4 Inhibitor I |
IRAK-1-4 Inhibitor I is an inhibitor of interleukin-1 receptor associated kinase (IRAK) with IC50 values of 0.3 μM and 0.2 μM for IRAK-1 and IRAK-4, respectively. It displays IC50 values >10 µM in a panel of 27 other kinases tested. |
Pan |
IRAK-4, IC50: 0.2 μM |
